Research programme: motor neuron disease gene therapy - Oxford BioMedica

Drug Profile

Research programme: motor neuron disease gene therapy - Oxford BioMedica

Alternative Names: Amyotrophic lateral sclerosis gene therapy - Oxford BioMedica; MoNuDin; OXB-103; SMN-1G; Spinal muscular atrophy gene therapy - Oxford BioMedica

Latest Information Update: 25 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oxford BioMedica; The Cleveland Clinic Foundation
  • Developer Katholieke Universiteit Leuven; Oxford BioMedica; VIB
  • Class Gene therapies; Spinal muscular atrophy gene therapies
  • Mechanism of Action Angiogenesis modulating agents; Gene transference; Genetic transcription stimulants; Survival of motor neuron 1 protein expression stimulants; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Amyotrophic lateral sclerosis; Motor neuron disease

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Motor neuron disease; Spinal muscular atrophy

Most Recent Events

  • 25 Jan 2011 Preclinical development is ongoing in United Kingdom
  • 25 Jan 2011 Oxford BioMedica's motor neuron disease gene therapy is still available for licensing
  • 01 Jul 2010 Preclinical trials in Amyotrophic lateral sclerosis in Belgium (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top